Immunic Net Income From Continuing Ops vs Total Other Income Expense Net Analysis
| IMUX Stock | USD 1.30 0.04 3.17% |
Immunic financial indicator trend analysis is infinitely more than just investigating Immunic recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunic is a good investment. Please check the relationship between Immunic Net Income From Continuing Ops and its Total Other Income Expense Net accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
Net Income From Continuing Ops vs Total Other Income Expense Net
Net Income From Continuing Ops vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunic Net Income From Continuing Ops account and Total Other Income Expense Net. At this time, the significance of the direction appears to have no relationship.
The correlation between Immunic's Net Income From Continuing Ops and Total Other Income Expense Net is 0.08. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Immunic, assuming nothing else is changed. The correlation between historical values of Immunic's Net Income From Continuing Ops and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Immunic are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Net Income From Continuing Ops i.e., Immunic's Net Income From Continuing Ops and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.08 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Net Income From Continuing Ops
Total Other Income Expense Net
Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 66K | 1.0M | 3.1M | 3.2M | Interest Income | 66K | 1.0M | 3.1M | 3.2M |
Immunic fundamental ratios Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
| Other Current Liab | 343K | 4.7M | 585K | 8.2M | 18.9M | 19.9M | |
| Total Current Liabilities | 7.1M | 8.4M | 11.4M | 13.1M | 24.7M | 26.0M | |
| Total Stockholder Equity | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
| Property Plant And Equipment Net | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
| Net Debt | (28.8M) | (126.8M) | (86.3M) | (105.2M) | (45.3M) | (47.6M) | |
| Retained Earnings | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (410.9M) | (390.3M) | |
| Accounts Payable | 2.4M | 3.7M | 3.7M | 4.3M | 5.1M | 3.9M | |
| Cash | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
| Non Current Assets Total | 33.7M | 34.1M | 34.1M | 1.9M | 1.8M | 1.7M | |
| Cash And Short Term Investments | 29.4M | 127.5M | 86.9M | 116.4M | 46.7M | 66.0M | |
| Common Stock Shares Outstanding | 7.7M | 15.7M | 23.7M | 31.8M | 44.3M | 46.5M | |
| Liabilities And Stockholders Equity | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
| Non Current Liabilities Total | 520K | 679K | 584K | 992K | 639.0K | 607.0K | |
| Other Current Assets | 2.9M | 1.2M | 18.1M | 9.5M | 5.2M | 4.1M | |
| Other Stockholder Equity | 53.7M | 266.8M | 324.2M | 427.9M | 436.1M | 245.3M | |
| Total Liab | 7.6M | 9.1M | 12.0M | 14.1M | 25.4M | 26.6M | |
| Property Plant And Equipment Gross | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
| Total Current Assets | 32.2M | 133.7M | 105.0M | 125.9M | 52.5M | 70.8M | |
| Accumulated Other Comprehensive Income | (1.4M) | (4.1M) | (252K) | 3.0M | 3.8M | 3.9M | |
| Non Currrent Assets Other | 108K | 37K | 42K | 43K | 38.7K | 36.8K | |
| Net Tangible Assets | 25.4M | 125.8M | 94.1M | 113.7M | 130.7M | 80.6M | |
| Retained Earnings Total Equity | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (285.6M) | (299.8M) | |
| Capital Surpluse | 119.6M | 266.8M | 324.2M | 427.9M | 492.1M | 326.3M | |
| Non Current Liabilities Other | 520K | 679K | 584K | 992K | 1.1M | 1.2M | |
| Property Plant Equipment | 80K | 203K | 1.1M | 294K | 264.6K | 251.4K | |
| Other Assets | 37K | 42K | 943K | 43K | 49.5K | 47.0K | |
| Net Receivables | 408K | 1.6M | 2.2M | 2.7M | 703K | 1.3M | |
| Net Invested Capital | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
| Net Working Capital | 25.2M | 125.3M | 93.6M | 112.8M | 27.8M | 26.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.